Wolverine Trading, LLC Immuno Gen, Inc. Call Options Transaction History

Wolverine Trading, LLC

$93.9 Billion
Q3 2024

Call Options

18 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2023 Feb 14, 2024	BUY	$12.46 - $29.95 $530,796 - $1.28 Million	42,600 New	42,600 $1.26 Million
Q1 2023 May 15, 2023	BUY	$3.67 - $4.92 $83,676 - $112,176	22,800 New	22,800 $85,000
Q3 2022 Nov 14, 2022	BUY	$4.48 - $6.47 $63,168 - $91,227	14,100 New	14,100 $66,000
Q4 2021 Feb 14, 2022	SELL	$4.75 - $7.5 $117,800 - $186,000	-24,800 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$5.02 - $6.59 $11,043 - $14,498	-2,200 Reduced 8.15%	24,800 $140,000
Q2 2021 Aug 06, 2021	BUY	$5.79 - $8.6 $156,330 - $232,200	27,000 New	27,000 $177,000
Q4 2020 Feb 12, 2021	SELL	$3.7 - $7.66 $64,010 - $132,518	-17,300 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$3.45 - $4.89 $13,455 - $19,071	3,900 Added 29.1%	17,300 $62,000
Q2 2020 Aug 13, 2020	SELL	$3.32 - $5.34 $6,640 - $10,680	-2,000 Reduced 12.99%	13,400 $59,000
Q1 2020 May 11, 2020	SELL	$2.12 - $6.8 $17,172 - $55,080	-8,100 Reduced 34.47%	15,400 $55,000
Q4 2019 Feb 12, 2020	BUY	$2.25 - $5.8 $27,225 - $70,180	12,100 Added 106.14%	23,500 $119,000
Q3 2019 Nov 14, 2019	SELL	$2.22 - $3.39 $122,766 - $187,467	-55,300 Reduced 82.91%	11,400 $31,000
Q1 2019 May 15, 2019	BUY	$2.41 - $5.91 $28,438 - $69,738	11,800 Added 21.49%	66,700 $181,000
Q4 2018 Feb 14, 2019	BUY	$3.94 - $9.7 $100,470 - $247,349	25,500 Added 86.73%	54,900 $247,000
Q3 2018 Nov 14, 2018	BUY	$8.6 - $11.26 $252,840 - $331,044	29,400 New	29,400 $278,000
Q1 2018 May 15, 2018	SELL	$6.7 - $12.95 $190,280 - $367,780	-28,400 Closed	0 $0
Q4 2017 Feb 14, 2018	SELL	$5.07 - $7.92 $132,327 - $206,712	-26,100 Reduced 47.89%	28,400 $182,000
Q3 2017 Nov 15, 2017	BUY	$5.4 - $8.47 $294,300 - $461,615	54,500	54,500 $417,000

Others Institutions Holding IMGN

# of Institutions

Shares Held

1.41M

Call Options Held

Put Options Held

View Full List

About ImmunoGen, Inc.

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

More about IMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wolverine Trading, LLC with notifications on news.

Account